Many newly diagnosed patients receive multiple myeloma treatment for more than 12 months, according to data collected from treatment centers around the world, showing that the shift away… read more.
Progression-free survival (PFS) and overall survival (OS) were improved similarly with maintenance therapy with lenalidomide or bortezomib in two studies presented at the International Myeloma Workshop. Written by… read more.
Preliminary results from a real-world study show that patients at an older age with a high comorbidity burden had their normal activities uninterrupted when they switched to the… read more.
“The genome can be thought of as the hardware driving a cell whereas the epigenome is more like the software – it is dynamic and erasable”, said Professor Ari… read more.
Prof Stephen Ansell (Rochester, USA) discusses how the new cellular technologies are being integrated into standard practice.Written by Esther Drain.
The first CAR T-cell treatment was administered in 2010 but the field has developed rapidly since then and in the first quarter of 2018 more than 100 trials… read more.
Checkmate 205, Cohort D. The results of the two-year, post-treatment follow-up of the Checkmate 205, Cohort D study group suggests that nivolumab followed by nivolumab + AVD could… read more.
Although early stage HL patients have an outstanding result, according to Prof Stephen Ansell (Rochester, USA), he argues that those with stage 3 and 4 disease don’t do nearly as… read more.
Prof Peter Johnson (Southampton, UK) discusses where there is consensus and controversy in the management of HL in 2019, as well as talking about the key takeaways from his… read more.
Professor Andrew Davies (Southampton, UK) discussed his presentation on double hit lymphoma. Written by Christine Clark.
Prof Andy Davies (Southampton, UK) discusses 2 important abstracts presented in the plenary session at ICML looking at whether there was a benefit to adding lenalidomide to RCHOP for… read more.
To give you a flavour of key recent advances in the management of lymphoma we asked in this video a group of experts at ICML this summer what… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
